New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
The failure of OV101 puts the spotlight on Ultragenyx and Roche.
A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.
The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.
The focus shifts to whether the FDA will overrule its own panel and approve the Alzheimer’s project.